As the world moves beyond the acute phase of the COVID-19 pandemic, efforts to prepare for future health crises are intensifying, particularly in Southeast Asia. The prospect of Disease X—an as-yet unidentified pathogen with pandemic potential—remains a pressing concern, underscoring the need to strengthen regional and global health systems.
Singapore has positioned itself as a key player in this evolving landscape, with Health Minister Ong Ye Kung emphasizing the importance of accelerating vaccine approval processes. He suggested that Singapore’s Health Sciences Authority could support international regulatory bodies like the World Health Organization (WHO) by sharing the burden of vaccine evaluations. This initiative aligns with Singapore’s ongoing investment in mRNA vaccine development, genomic surveillance, and regional partnerships to enhance pandemic preparedness.
The COVID-19 crisis highlighted critical vulnerabilities in global health governance, particularly the dependence of many countries on external vaccine supplies, procurement decisions, and aid distribution. These challenges sparked calls for a more sovereign approach to health security, one that empowers nations to safeguard their populations more directly. Ghana’s President John Dramani Mahama recently highlighted this need at the United Nations, advocating for a “reset” in global health architecture that shifts from donor-driven assistance toward country-led priorities, supported by regional and global collaboration where appropriate.
In Southeast Asia, this approach calls for a calibrated distribution of capabilities. While no single country must own every function, each government must develop core capacities to detect threats, make informed decisions, and protect its citizens. More specialized resources—such as high-level regulatory expertise, vaccine manufacturing, and genomic surveillance—can be shared regionally. ASEAN’s existing frameworks, including its Joint Assessment Procedure for medicines, could evolve to enable greater regulatory reliance, with Singapore and Indonesia leading as WHO-recognized authorities.
Regional cooperation could extend to procurement strategies as well. Thailand, with its existing role in vaccine security, might collaborate with neighboring countries to pool demand for vaccines, antibiotics, and essential medicines. This aggregated purchasing power could yield better prices, improved supply certainty, and benefits for smaller markets such as Brunei, Laos, Cambodia, and Timor-Leste.
Singapore’s broader contributions encompass convening stakeholders across governments, multilateral organizations, philanthropic groups, and industry to identify gaps and coordinate resources. The city-state’s institutional expertise—from regulatory frameworks to public health initiatives—and its emerging philanthropic ecosystem offer valuable resources to support regional capacity building. However, efforts will focus on adapting policies and knowledge to local contexts rather than exporting one-size-fits-all models.
Additionally, Singapore’s academic institutions have a role in supporting sustainable health systems by fostering expertise within the region. Developing local capacities in epidemiology, health economics, public health law, and related fields is critical to achieving long-term health sovereignty beyond reliance on external assistance.
Looking ahead, Singapore’s upcoming chairmanship of ASEAN in 2027 presents an opportunity to advance these collaborative efforts. By leveraging its strengths in institution-building, multilateral engagement, and accountability, Singapore aims to help establish a more resilient and sovereign regional health architecture. This model seeks to balance national capabilities with strategic regional and global cooperation, positioning Southeast Asia to respond more effectively to Disease X and future pandemics.